Physician profile
Samuel A Giday
NPI 1598716110
$2,033,721.36
in general payments reported to CMS, 2019-2025
23 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.1M · 2020: $606K · 2021: $339K · 2022: $188 · 2023: $298 · 2024: $380 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157 · Travel and Lodging: $803 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.23 |
| Travel and Lodging | $803.04 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Incorporated | $2,029,192.31 | 2019-2021 | |
| Adare Pharmaceuticals, INC. | $1,503.61 | 2020 | |
| Abbvie INC. | $1,045.53 | 2019-2025 | |
| Medtronic, INC. | $819.70 | 2025 | Gi Genius |
| Janssen Biotech, INC. | $187.77 | 2019-2025 | Tremfya |
| Madrigal Pharmaceuticals | $149.64 | 2024 | Rezdiffra |
| Olympus America INC. | $136.15 | 2019-2024 | Evis Exera III Colonovideoscope |
| Medical Device Business Services, INC. | $116.50 | 2019 | |
| Angiodynamics, INC. | $103.12 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $86.74 | 2025 | Iqirvo |
| Genzyme Corporation | $65.84 | 2024-2025 | |
| Celgene Corporation | $50.23 | 2021-2024 | Zeposia |
| Pentax of America, INC. | $48.08 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Novo Nordisk INC | $47.52 | 2025 | Wegovy |
| Qol Medical, LLC | $38.71 | 2019-2023 | Sucraid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $24.31 | 2023 | Suflave |
| Intercept Pharmaceuticals, INC. | $20.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.72 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $16.32 | 2020 | |
| Intra-Sana Laboratories | $14.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.16 | 2020 | |
| Allergan, INC. | $12.20 | 2019 | |
| Pfizer INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Giday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.